Location Directory

Clinical trials in Jacksonville, Florida

This page shows live ClinicalTrials.gov search results for Jacksonville, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

7646

Shown on this page

Current sort

Institutions in Jacksonville

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Mayo Clinic

Live official records

Open in full search

Conditions: Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Pembrolizumab; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 533
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 340 more

Conditions: Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor, Metastatic Cancer, WNT Pathway, HCC, Desmoid, Microsatellite Stable Colorectal Cancer, Metastatic Castration-resistant Prostate Cancer, Familial Adenomatous Polyposis (FAP), Endometrial Carcinoma, Prostate Cancer, Microsatellite Instability-High Colorectal Cancer, Adamantinomatous Craniopharyngioma
Interventions: FOG-001, mFOLFOX-6, Nivolumab, Trifluridine/tipiracil, Bevacizumab; Drug
Lead sponsor: Parabilis Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 619 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 31
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 25 more

Conditions: Stroke, Chronic Stroke Patients, Cerebrovascular Accident (CVA)
Interventions: Device: Q Therapeutic System (BQ 3.0) - Active; Device
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Coronary Arterial Disease (CAD), Percutaneous Coronary Intervention (PCI)
Interventions: Prasugrel, Clopidogrel; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions: Survey Administration; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 625 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 6
States / cities: Tuscaloosa, Alabama • La Jolla, California • Jacksonville, Florida + 2 more

Conditions: Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma
Interventions: Surgery, Preoperative chemotherapy; Procedure · Drug
Lead sponsor: European Organisation for Research and Treatment of Cancer - EORTC; Network
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 116
States / cities: Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 92 more

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions: Biospecimen Collection, Letermovir; Procedure · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 2 Years to 18 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 33
States / cities: Birmingham, Alabama • Oakland, California • San Francisco, California + 28 more

Conditions: Head and Neck Carcinoma, Malignant Parotid Gland Neoplasm, Maxillary Sinus Carcinoma, Nasal Cavity Carcinoma, Oral Cavity Carcinoma, Tongue Carcinoma, Tonsillar Carcinoma
Interventions: Best Practice, Medical Device Usage and Evaluation; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 7
States / cities: Phoenix, Arizona • Jacksonville, Florida • Indianapolis, Indiana + 2 more

Conditions: Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma, Refractory Primary Central Nervous System Lymphoma
Interventions: Emavusertib, Ibrutinib; Drug
Lead sponsor: Curis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 27
States / cities: Phoenix, Arizona • Duarte, California • Santa Monica, California + 19 more

Conditions: Soft Tissue Sarcoma
Interventions: Palifosfamide-Tris, doxorubicin, Placebo; Drug
Lead sponsor: Alaunos Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 73
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 65 more

Conditions: cGVHD
Interventions: Non-Interventional; Other
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 30 more

Conditions: Pre-Exposure Prophylaxis of HIV Infection
Interventions: Oral Lenacapavir (LEN), F/TDF, Sub-cutaneous (SC) Lenacapavir (LEN), Placebo SC LEN, PTM F/TDF, PTM Oral LEN, F/TAF (for US participants only); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 16 Years and older
Enrollment: 3,292 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2028
U.S. locations: 60
States / cities: Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 43 more

Clinical trials in Jacksonville, Florida

Filter and sort this location

Institutions in Jacksonville

Live official records

Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

FOG-001 in Locally Advanced or Metastatic Solid Tumors

RESPARK - Brain Q for Chronic Stroke

Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)

Financial Toxicity in Cancer Patients

Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients

Customized 3D Printed Oral Stents During Head and Neck Radiotherapy

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma

Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease

Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV Infection